Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Efficacy And Safety Of Sultamicillin (ampicillin/sulbactan) And Amoxicillin/clavulanic Acid In The Treatment Of Upper Respiratory Tract Infections In Adults - An Open-label, Multicentric, Randomized Trial [eficácia E Segurança De Sultamicilina (ampicilina/sulbactam) E Amoxacilina/clavulanato No Tratamento Das Infecções De Via Aéreas Superiores Em Adultos - Um Estudo Multicêntrico, Aberto E Randomizado]
Author: Ferreira J.B.
Rapoport P.B.
Sakano E.
Kos A.O.D.A.
Piltcher O.B.
Pignatari S.S.N.
Pinheiro S.D.
Mocellin M.
Abstract: Upper respiratory tract infections are the most common causes of medical visits in children and adults, demanding massive use of antibiotics. Bacterial resistance caused by beta-lactamase is one of the most serious problems in this matter. Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, is a potent beta-lactamase inhibitor which can face this challenge. Aim: evaluate efficacy, safety and tolerability of Ampicillin/Sulbactan compared to Amoxicillin/ Clavulanate in upper respiratory tract infections in adults. Methods: 102 patients were enrolled and randomized to receive Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 days. They were evaluated 10 and 30 days after treatment to learn about the therapeutic response. Results: There were no differences between the two groups respecting cure at the end of treatment (visit 2) or at the end of the study (visit 3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, respectively, in Ampicillin/Sulbactan group. The adverse events ratio for the two groups was the same (p=0.940). The number of patients with diarrhea was greater in the group of patients receiving Amoxicillin/Clavulanate (70.6%) than in the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). Conclusions: Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults. The low occurrence of diarrhea in the group receiving Ampicillin/Sulbactan needs confirmation in other studies.
Rights: aberto
Identifier DOI: 
Date Issue: 2006
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-33747429783.pdf154.59 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.